i
Important informations
Instagram
Portal
Donate now

News and Events

LDI Research News

Read about the latest advances from the Lady Davis Institute for Medical Research (LDI) and its researchers, including new findings, grant awards, innovations, and collaborations.

LDI logo

New study links GLP-1 receptor agonists to increased risk of gastroesophageal reflux disease (GERD) in type 2 diabetes patients

The study shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which include Ozempic®, Rybelsus® and other widely- prescribed drugs for type 2 diabetes and obesity management, may increase the risk of developing gastroesophageal reflux disease (GERD) and its complications compared to sodium–glucose cotransporter-2 (SGLT-2) inhibitors (such as Brenzavvy™, Invokana®, etc.).
Read more
LDI logo

New study reveals promising strategy to retrain neutrophils to target breast cancer

Innovative strategy has the potential to revolutionize the treatment of breast cancer, particularly for patients who have developed resistance to targeted therapies.
Read more
LDI logo

Lady Davis Institute researchers and research trainees distinguish themselves in the Fonds de recherche du Québec (FRQ) 2025-2026 competitions

Nine researchers, one postdoctoral fellow, 17 PhD students and three master’s students from the Lady Davis Institute for Medical Research (LDI) are the recipients of FRQ salary and research awards within the framework of the 2025-2026 competitions.
Read more
LDI logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.